文献速递男科与性医学

成年男性性腺功能减退症的睾酮治疗

Testosterone Therapy in Adult Males with Hypogonadism.
PubMed 文献 · Eur Urol · 2025-12-24

本文为非系统性综述,总结睾酮治疗(TTh)在成年男性睾酮缺乏症(TD)中的证据。TD症状常轻微非特异,诊断需临床评估及血清总睾酮降低确认。TTh可改善性功能、体成分、代谢及骨密度,不增加主要心血管事件或前列腺癌风险,指南建议睾酮维持在450-600 ng/dl并监测相关指标。

要点

  • TD症状轻微非特异,诊断需临床评估加血清总睾酮降低确认。
  • TTh改善性功能、体成分、代谢及骨密度,不增加主要心血管事件或前列腺癌风险。
  • 指南建议睾酮维持在450-600 ng/dl,监测血细胞比容、PSA及代谢指标。

核心结论

  • TTh是TD安全有效的治疗方法,产品选择应考虑患者需求、偏好及医生观点。

研究设计与样本

  • 非系统性文献综述,检索诊断和治疗TD的相关研究,涵盖生活方式和药物方法。

主要发现

  • TTh改善性功能、体成分、代谢 profile 和骨密度,不增加主要心血管事件或前列腺癌风险。

关键数值与推荐

  • 指南推荐睾酮维持在正常范围中值(450-600 ng/dl)。
  • 监测血细胞比容、前列腺特异性抗原和代谢参数。
  • 随访应在3个月时进行,之后每6-12个月一次,根据临床反应和安全进行个体化调整。

临床怎么用

  • 对症状性TD且睾酮水平低的男性,TTh是标准治疗。
  • 根据患者需求、偏好及医生观点选择最合适的产品。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Testosterone deficiency (TD) is a common condition affecting patients' health and quality of life. Clinical management has changed over the past decades, particularly regarding the indications and outcomes of testosterone therapy (TTh). Our aim was to provide an overview of the available evidence supporting the use of TTh in adult men with TD. METHODS: A nonsystematic literature review was conducted to identify relevant studies on the diagnosis and treatment of TD. The review encompassed lifestyle and pharmacological approaches, summarizing recent advances and highlighting persisting gaps in clinical practice. KEY FINDINGS AND LIMITATIONS: Testosterone deficiency in adult men typically presents with mild, nonspecific symptoms often related to aging, including sexual dysfunction, fatigue, mood changes, and reduced muscle and bone mass. Diagnosis requires a thorough clinical assessment and confirmation of low serum total testosterone. TTh is the standard treatment for symptomatic men with TD and low testosterone levels. Evidence indicates that TTh improves sexual function, body composition, metabolic profile, and bone mineral density without increasing the risk of major cardiovascular events or prostate cancer. Current guidelines recommend maintaining testosterone within the midnormal range (450-600 ng/dl) and monitoring hematocrit, prostate-specific antigen, and metabolic parameters. Follow-up should occur at 3 mo and every 6-12 mo thereafter, with individualized adjustments based on clinical response and safety. CONCLUSIONS AND CLINICAL IMPLICATIONS: TTh is a safe and effective treatment for TD. The selection of the most suitable product should consider patient needs and preferences, as well as the physician's perspective.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Boeri L, Masterson T, Antonio L, et al. Testosterone Therapy in Adult Males with Hypogonadism. Eur Urol. 2025. PMID: 41448986. doi:10.1016/j.eururo.2025.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。